Lutetium (¹⁷⁷Lu) vipivotide tetraxetan clinical trials
Also written 177Lu-PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan, Pluvicto and AAA617.
How each study uses lutetium (¹⁷⁷Lu) vipivotide tetraxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lutetium (¹⁷⁷Lu) vipivotide tetraxetan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2025 (12)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 11 |
| 2025 | 12 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 41
Novartis Pharmaceuticals (7) · Peter MacCallum Cancer Centre, Australia (3) · University of California, San Francisco (3) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (2) · Dana-Farber Cancer Institute (2) · Weill Medical College of Cornell University (2) · Radboud University Medical Center (2)
Often tested with
Tested in the same studies.
Carboplatin (3) · Cabazitaxel (3) · Abiraterone Acetate (2) · Abiraterone (2) · Prednisone (2) · Gallium 68 PSMA-11 (1) · Ipilimumab (1) · Nivolumab (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Lutetium (¹⁷⁷Lu) vipivotide tetraxetan is the comparator. A study of two new drugs counts under both.
- 1Darolutamide · ECOG-ACRIN Cancer Research Group · next primary completion Mar 2029
Reaching primary completion within a year · 12
Studies that test lutetium (¹⁷⁷Lu) vipivotide tetraxetan.
- Nov 2026Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionPhase 2 · Novartis Pharmaceuticals
- Dec 2026177LuPSMA in Renal Cell CarcinomaPhase 2 · Dana-Farber Cancer Institute
- Dec 2026A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCPhase 2 · Novartis Pharmaceuticals
- Dec 2026Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerPhase 2 · Fred Hutchinson Cancer Center
- Jan 2027Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialPhase 2 · Jonsson Comprehensive Cancer Center
- Apr 2027Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617Phase 2 · Ebrahim S Delpassand
- Apr 2027Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617Phase 1 · Thomas Hope
- May 2027Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerPhase 2 · University of California, San Francisco
- May 2027Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerPhase 1/2 · Vadim S Koshkin
- Jul 2027177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical TrialPhase 4 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Studies
Open first, then newest update. How each study uses lutetium (¹⁷⁷Lu) vipivotide tetraxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)RecruitingPhase 1Jean-Mathieu BeauregardNCT06943495Written as 177Lu-PSMA-617
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate CancerRecruitingPhase 1University of California, San FranciscoNCT07145177Written as 177Lu-PSMA-617
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Lutetium Lu 177 Vipivotide Tetraxetan
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.RecruitingPhase 3Novartis PharmaceuticalsNCT05939414Written as AAA617
- Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialRecruitingPhase 2University of WashingtonNCT07698535Written as Lutetium Lu 177 Vipivotide Tetraxetan
- 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate CancerRecruitingPhase 2Maria Sklodowska-Curie National Research Institute of OncologyNCT06449781Written as Lutetium (177Lu) vipivotide tetraxetan
- Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerNot yet recruitingPhase 1University of Michigan Rogel Cancer CenterNCT07682649Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerNot yet recruitingPhase 2Emory UniversityNCT07860554Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerRecruitingPhase 2Case Comprehensive Cancer CenterNCT06738303Written as Lu-PSMA-617
- Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingPhase 2Mayo ClinicNCT07650240Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate AdenocarcinomaRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07150715Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingPhase 2University of California, San FranciscoNCT05766371Written as 177Lu-PSMA-617
- Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617RecruitingPhase 1Thomas HopeNCT07054346Written as 177 Lutetium Prostate-Specific Membrane Antigen 617
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06145633Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerRecruitingPhase 1/2Vadim S KoshkinNCT05113537Written as Lutetium Lu 177-PSMA-617
- Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseRecruitingPhase 2University of WashingtonNCT06526299Written as Lutetium Lu 177 Vipivotide Tetraxetan
- 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical TrialNot yet recruitingPhase 4The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07677566Written as Darolutamide combined with 177Lu-PSMA-617
- Radiopharmaceutical Treatment of Advanced Kidney CancerRecruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT06783348Written as 177Lu-PSMA-617
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruitingPhase 4Novartis PharmaceuticalsNCT05803941Written as AAA617
- A Study of 177Lu-PSMA-617 in People With GliomasRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07223034Written as 177Lu-PSMA-617
See all 50 studies that test lutetium (¹⁷⁷Lu) vipivotide tetraxetan →
Given beside what is tested · 10 — lutetium (¹⁷⁷Lu) vipivotide tetraxetan is usual care or a partner of the new treatment
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT06095089Written as Lutetium Lu-177 Vipivotide Tetraxetan
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Lutetium Lu-177 vipivotide tetraxetan
- Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07200830Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerRecruitingPhase 1Weill Medical College of Cornell UniversityNCT04886986Written as 177Lu-PSMA-617
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1City of Hope Medical CenterNCT07219147Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Randomized Phase II Trial of Targeted Radiation With no Castration for McrpcRecruitingPhase 2VA Office of Research and DevelopmentNCT06084338Written as Pluvicto
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT07047118Written as AAA617
- An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06894511Written as AAA617
- Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerSuspendedPhase 2Mayo ClinicNCT06200103Written as Lutetium Lu 177 Vipivotide Tetraxetan
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCActive, not recruitingPhase 1/2OncoC4, Inc.NCT05682443Written as lutetium Lu 177 vipivotide tetraxetan
As the comparator · 1 — what is tested is compared with lutetium (¹⁷⁷Lu) vipivotide tetraxetan
What changed recently
From the registry's own updates since Oct 17, 2026.
Codes
What other systems call lutetium (¹⁷⁷Lu) vipivotide tetraxetan · ClinicalTrials.gg INT000522
- MeSH (NLM) C000610110lutetium (177Lu) vipivotide tetraxetanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G6UF363ECXLUTETIUM LU-177 VIPIVOTIDE TETRAXETANConfirmed FDA, NLM, Wikidata
- RxNorm 2597053One source FDA
- Wikidata Q111353661lutetium (¹⁷⁷Lu) vipivotide tetraxetanConfirmed FDA, NLM, Wikidata
- DrugBank DB16778One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000610110 | lutetium (177Lu) vipivotide tetraxetan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G6UF363ECX | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2597053 | — | One source FDA |
| Wikidata | Q111353661 | lutetium (¹⁷⁷Lu) vipivotide tetraxetan | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB16778 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.